Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 211

Cited In for PubMed (Select 19536107)

1.

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.

Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, Ruhe J, Bange J, Nakamaru K, Chen S, Tsuchihashi Z, von Pawel J, Copigneaux C, Beckman RA.

EBioMedicine. 2015 Feb 12;2(3):264-71. doi: 10.1016/j.ebiom.2015.02.005. eCollection 2015 Mar.

2.

Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.

Blancafort A, Giró-Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ò, Carrión-Salip D, Massaguer A, Brugada R, Palafox M, Gómez-Miragaya J, González-Suárez E, Puig T.

PLoS One. 2015 Jun 24;10(6):e0131241. doi: 10.1371/journal.pone.0131241. eCollection 2015.

3.

Profile of neratinib and its potential in the treatment of breast cancer.

Feldinger K, Kong A.

Breast Cancer (Dove Med Press). 2015 Jun 9;7:147-62. doi: 10.2147/BCTT.S54414. eCollection 2015. Review.

4.

A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.

Dey N, Williams C, Leyland-Jones B, De P.

Am J Transl Res. 2015 Apr 15;7(4):733-50. eCollection 2015.

5.

HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide.

Chenard MP, Wissler MP, Weingertner N, Mathelin C, Bellocq JP.

Virchows Arch. 2015 Aug;467(2):169-75. doi: 10.1007/s00428-015-1781-0. Epub 2015 May 19.

6.

Evidence for archaic adaptive introgression in humans.

Racimo F, Sankararaman S, Nielsen R, Huerta-Sánchez E.

Nat Rev Genet. 2015 Jun;16(6):359-71. doi: 10.1038/nrg3936. Epub 2015 May 12. Review.

7.

Targeting Hsp90 in urothelial carcinoma.

Chehab M, Caza T, Skotnicki K, Landas S, Bratslavsky G, Mollapour M, Bourboulia D.

Oncotarget. 2015 Apr 20;6(11):8454-73. Review.

8.

Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.

Ren XR, Wang J, Osada T, Mook RA Jr, Morse MA, Barak LS, Lyerly HK, Chen W.

Breast Cancer Res. 2015 Feb 15;17:20. doi: 10.1186/s13058-015-0528-9.

9.

New clinical advances in immunotherapy for the treatment of solid tumours.

Zavala VA, Kalergis AM.

Immunology. 2015 Jun;145(2):182-201. doi: 10.1111/imm.12459. Epub 2015 Mar 30. Review.

PMID:
25826229
10.

Em08red, a dual functional antiproliferative emodin analogue, is a downregulator of ErbB2 expression and inducer of intracellular oxidative stress.

Liang FP, Lien JC, Wu YH, Chen CS, Juang SH.

Drug Des Devel Ther. 2015 Mar 12;9:1499-510. doi: 10.2147/DDDT.S66647. eCollection 2015.

11.

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.

Leung WY, Roxanis I, Sheldon H, Buffa FM, Li JL, Harris AL, Kong A.

Oncotarget. 2015 Mar 20;6(8):5678-94.

12.

Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop.

Yang Z, Guo L, Liu D, Sun L, Chen H, Deng Q, Liu Y, Yu M, Ma Y, Guo N, Shi M.

Oncotarget. 2015 Mar 10;6(7):5072-87.

13.

A global microRNA screen identifies regulators of the ErbB receptor signaling network.

Bischoff A, Bayerlová M, Strotbek M, Schmid S, Beissbarth T, Olayioye MA.

Cell Commun Signal. 2015 Jan 29;13:5. doi: 10.1186/s12964-015-0084-z.

14.

HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285.

Takagi S, Banno H, Hayashi A, Tamura T, Ishikawa T, Ohta Y.

Oncoscience. 2014 Mar 24;1(3):196-204. eCollection 2014.

15.

Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.

Spraggon L, Cartegni L.

Drug Discov Today Ther Strateg. 2013 Fall;10(3):e139-e148.

16.

Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas.

Tang D, Liu CY, Shen D, Fan S, Su X, Ye P, Gavine PR, Yin X.

Onco Targets Ther. 2014 Dec 16;8:7-14. doi: 10.2147/OTT.S70922. eCollection 2015.

17.

Examination of HER3 targeting in cancer using monoclonal antibodies.

Gaborit N, Abdul-Hai A, Mancini M, Lindzen M, Lavi S, Leitner O, Mounier L, Chentouf M, Dunoyer S, Ghosh M, Larbouret C, Chardès T, Bazin H, Pèlegrin A, Sela M, Yarden Y.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):839-44. doi: 10.1073/pnas.1423645112. Epub 2015 Jan 6.

18.

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.

Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N.

Sci Signal. 2014 Dec 2;7(354):ra114. doi: 10.1126/scisignal.2005786.

PMID:
25468994
19.

Regulation of ERBB3/HER3 signaling in cancer.

Mujoo K, Choi BK, Huang Z, Zhang N, An Z.

Oncotarget. 2014 Nov 15;5(21):10222-36. Review.

20.

Melatonin Attenuates Her-2, p38 MAPK, p-AKT, and mTOR Levels in Ovarian Carcinoma of Ethanol-Preferring Rats.

Ferreira GM, Martinez M, Camargo IC, Domeniconi RF, Martinez FE, Chuffa LG.

J Cancer. 2014 Oct 3;5(9):728-35. doi: 10.7150/jca.10196. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk